Patents Examined by Dameron Jones
  • Patent number: 6071490
    Abstract: A method of delivering Ga-68 to a target site is effected by administering a bi-specific antibody which specifically binds via a primary binding site to a substance produced by or associated with the target site and which specifically binds via a secondary binding site to a subsequently administered chelate-Ga-68 complex, and allowing the antibody to localize at the target site; optionally administering a clearing agent to clear non-localized bi-specific antibody rapidly from circulation; and administering a chelate-Ga-68 complex comprising Ga-68 chelated to Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH.sub.2 and allowing the chelate-Ga-68 complex to localize at the target site via specific binding by the secondary binding site of the bi-specific antibody. The targeted complex then can be used for PET imaging to give highly resolved images. Alternatively, the Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH.sub.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: June 6, 2000
    Assignee: Immunomedics, Inc.
    Inventors: Gary L. Griffiths, William J. McBride
  • Patent number: 6071491
    Abstract: Disclosed are methods for identifying the presence of a tumor in a mammal, comprising the steps of obtaining an antibody against cell ghosts, wherein the antibody is specific to an intracellular antigen not present on the cell surface of normal or neoplastic cells, and wherein the antibody is labeled with a label capable of being imaged; administering the antibody to the mammal, thereby permitting the antibody to bind preferentially to necrotic tissue; and imaging the binding of the antibody to the necrotic tissue, wherein a localized concentration of said antibody is indicative of the presence of a tumor. The antibodies used in these methods are preferably monoclonal antibodies, are also preferably specific for one or more nuclear proteins, and are also preferably labeled with one or more radionuclides. Also disclosed are antibodies for use with the foregoing methods.
    Type: Grant
    Filed: August 9, 1999
    Date of Patent: June 6, 2000
    Assignee: Techniclone, Inc.
    Inventors: Alan L. Epstein, Clive R. Taylor
  • Patent number: 6066309
    Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: May 23, 2000
    Assignee: RhoMed Incorporated
    Inventors: Paul O. Zamora, Michael J. Merek
  • Patent number: 6056940
    Abstract: This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: May 2, 2000
    Assignee: Diatide, Inc.
    Inventors: William McBride, Richard T. Dean, John Lister-James, Edward R. Civitello
  • Patent number: 6056939
    Abstract: Metal complexes of new ligands of the formula ##STR1## are useful as agents for medical imaging, particularly MRI, for in vitro or in vivo diagnostic or as radiopharmaceuticals. In these compounds, X--R.sup.1 --Y is a coordinating group able to form a highly stable complex with metal ions. Suitable units are for example derivatives of ortho-phenanthroline or of an hydroxamic acid. R.sup.2 and R.sup.3 are reactive functions such as amines or carboxylic groups. R.sup.4 and R.sup.5 are ligands, for instance diethylenetriaminepentaacetic acid 1,4,7,10-tetraacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,8,11-tetraazacyclotetradecane-N, N', N", N'"-tetraacetic acid (TETA), of a different type than the X--R.sup.1 --Y units and able to strongly encapsulate metal ions with which the X--R.sup.1 --Y moieties form less stable chelates.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: May 2, 2000
    Inventors: Jean F. Desreux, Vincent Jacques, Valerie Humblet, Martine Hermann, Vinciane Comblin-Tholet, Michael F. Tweedle
  • Patent number: 6056941
    Abstract: A kit containing a solution of boronic acid adducts of technetium-99 m dioxime complexes; and hydroxypropyl gamma cyclodextrin to maintain the solution free of particulate matter originating from the formulation.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: May 2, 2000
    Assignee: Bracco Research USA
    Inventors: Ernest Schramm, Margaret Newborn, Julius P. Zodda, Thomas Katona, Jo Anna Monteferrante
  • Patent number: 6051206
    Abstract: This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: April 18, 2000
    Assignee: Diatide, Inc
    Inventors: Richard T. Dean, John Lister-James, William McBride
  • Patent number: 6051209
    Abstract: A method of evaluating the effects of administering an external stimuli or treatment such as a psychoactive compound, a drug, or an environmental influence like temperature, noise, vibration, light and similar sensory-perceived influences, on a subject's brain using imaging techniques with positron emission tomography (PET). The method measures cerebral metabolism before and after administering the external stimuli or treatment, and employs a behavioral clamp to control behavioral influences on the subject's brain after administration of the external stimuli or treatment.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: April 18, 2000
    Inventors: John T. Metz, Malcolm D. Cooper
  • Patent number: 6051207
    Abstract: The invention provides a composition of matter of the formula (I): V-L-R where V is a non-peptidic organic group having binding affinity for an endothelin receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body. This composition of matter may be used to image diseases and disorders, particularly of the cardiovascular system.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 18, 2000
    Assignee: Nycomed Imaging AS
    Inventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson, Magne Solbakken
  • Patent number: 6027711
    Abstract: A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:R.sub.1 --X--R.sub.2where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: February 22, 2000
    Assignee: RhoMed Incorporated
    Inventor: Shubh D. Sharma
  • Patent number: 6027710
    Abstract: The present invention provides a radiation-protecting agent which protects the active ingredient of radiopharmaceuticals against the radiolysis caused by a reaction of the active ingredient with water radicals formed by radiolysis of water, without decomposing the reactive active ingredient such as readily reducible active ingredient. The radiation-protecting agent of the present invention is characterized by comprising an organic compound usable in medical drugs and having high physiological acceptability and protecting the radiolabeled active ingredient of radiopharmaceuticals against the action of radiation. The reaction rate constant of said organic compound with OH radical, H radical or hydrated electron must be in the range of from 1.times.10.sup.8 to 5.times.10.sup.10 M.sup.-1 s.sup.-1, and when added to radiopharmaceuticals, molar concentration of the organic compound must be at least 50 times as high as molar concentration of the active ingredient.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: February 22, 2000
    Assignee: Nihon Medi-Physiscs Co., Ltd.
    Inventors: Kazuo Higashi, Komei Washino
  • Patent number: 6027709
    Abstract: New fluorescent cyanine dyes are useful as reporter groups for labeling biomolecules.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: February 22, 2000
    Assignee: Li-Cor Inc.
    Inventors: Garrick Murray Little, Ramesh Raghavachari, Narasimhachari Narayanan, Harry Leonard Osterman
  • Patent number: 6024938
    Abstract: A lyophilized imaging agent formulation and methods for making same are disclosed, such formulations comprise a targeting molecule such as antibody or chemotactic peptide, a linker such as diethylenetriaminepentaacetic acid (DTPA) or succinimidyl 6-hydrazinium nicotinate hydrochloride (SHNH), drying protectant such as mannitol, maltose or tricine, and excipient such as polysorbate 80, in citrate buffer. The formulations of the invention are lyophilized and may be stored stably for extended periods of time. Following reconstitution with diluent, the formulations are administered to a subject for scintigraphic imaging or therapeutic use. Also contemplated is a kit comprising a two-vial system wherein a first vial comprises a lyophilized formulation of imaging agent in the form of a lyophilized cake, and a second vial comprises a pharmaceutically acceptable carrier or diluent.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: February 15, 2000
    Assignees: Ortho Pharmaceutical Corporation, Johnson-Matthey Inc.
    Inventors: Diane C. Corbo, Mary Jean M. Link, N. Adeyinka Williams, Michelle L. Tomsho, Michael Bornstein, Howard F. Solomon, Scott K. Larsen, Robert L. Suddith
  • Patent number: 6022522
    Abstract: Bicyclo[2.2.2]octane-2,3 diamine-N,N,N',N'-tetraacetic acids (BODTA) and bicyclo[2.2.1]heptane-2,3 diamine-N,N,N',N'-tetraacetic acid (BHDTA) are chelating agents useful in forming detectably labeled bioconjugate compounds for diagnostic and therapeutic purposes. New compounds and processes of forming BODTA and BHDTA are disclosed. Radioimmunoconjugates of the present invention show high and prolonged tumor uptake with low normal tissue uptakes.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: February 8, 2000
    Assignee: Brookhaven Science Associates
    Inventors: Mark P. Sweet, Ronnie C. Mease, Suresh C. Srivastava
  • Patent number: 6017511
    Abstract: A peptide-chelator conjugate that is useful for imaging sites of inflammation in humans comprises a metal chelator coupled to a glycopeptide antibiotic. The metal chelator and the glycopeptide are coupled by a linking group. The linking group may be the divalent radical NH--(CH.sub.2).sub.3 --NH. Alternatively the linking group may be .beta.Ala.sub.3 LysGly-OH and the glycopeptide may be coupled to the N.sup..epsilon. of Lys. A method of imaging a site of inflammation is also provided. The method comprises the step of administering a diagnostically effective amount of a composition comprising a glycopeptide-chelator conjugate comprising a metal chelator coupled to a glycopeptide antibiotic. The glycopeptide-chelator conjugate is in a form complexed with a diagnostically useful metal or an oxide or nitride thereof.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: January 25, 2000
    Assignee: Resolution Pharmaceuticals Inc.
    Inventors: Ernest Wong, Theresa Fauconnier, Tam Nguyen, Alfred Pollak, Suman Rakhit
  • Patent number: 6017514
    Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: January 25, 2000
    Assignee: Techniclone Inc.
    Inventors: Alan L. Epstein, Clive R. Taylor
  • Patent number: 6017509
    Abstract: This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: January 25, 2000
    Assignee: Diatide, Inc.
    Inventors: Richard T. Dean, William McBride, John Lister-James
  • Patent number: 6017513
    Abstract: A novel method for the mucosal administration of a substance to a mammal is provided. The method comprises contacting a mucosal surface of the mammal with the substance in combination with a Biovector. The Biovector has a core that comprises a natural polymer, or a derivative or a hydrolysate of a natural polymer, or a mixture thereof. A preferred natural polymer is a polysaccharide or an oligosaccharide. The core is optionally coated with an amphiphilic compound, such as a lipid.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: January 25, 2000
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Alain Etienne, Ignacio de Miguel, Roger Kravtzoff, Michel Major
  • Patent number: 6017512
    Abstract: This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: January 25, 2000
    Assignee: Diatide, Inc.
    Inventors: Richard T. Dean, William McBride, John Lister-James
  • Patent number: 6015544
    Abstract: A process for producing a carrier free radio halogenated 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imida zo[1,5-a][1,4]-benzodiazepine of formula (II) where R.sup.1 is a radioactive halogen and R.sup.1 may be at 7, 8, 9 or 10 substituent. The above compound is used in a pharmaceutical composition for nuclear medicine examination.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: January 18, 2000
    Assignee: Map Medical Technologies Oy
    Inventors: Christian Foged, Christer Halldin, Jukka Hiltunen, Lars Farde